16/10/2026 US FDA approved Roche’s satralizumab for TED US FDA approved UCB’s zilucoplan autoinjector adults with gMG Novartis halted a mid-stage Fablhalta study in lupus nephritis US FDA approved Roche’s satralizumab for TED (Ref) Roche’s Enspryng® (satralizumab; IL-6R inhibitor) received US FDA approval as the first and only at-home subcutaneous treatment for adults with thyroid eye disease (TED).The approval was based on Ph3, SatraGO-1 and SatraGO -2 studies. SatraGO-2 sho

10/09/2026 US FDA granted Priority Review to Roche’s Enspryng for MOGAD US FDA granted Priority Review to Roche’s Enspryng for MOGAD. (Ref) Roche announced that the US FDA had granted Priority Review to a supplemental Biologics License Application (sBLA) for Enspryng® (satralizumab; anti- IL-6) for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The filing acceptance was based on positive results from the Phase 3, METEOROID study, whi

30/06/2026 FDA granted priority review to Roche’s satralizumab as a treatment option for TED FDA granted priority review to Roche’s satralizumab as a treatment option for TED (Ref) Roche announced that the US FDA had accepted and granted priority review to a supplemental Biologics License Application (sBLA) for Enspryng® (satralizumab) for the treatment of thyroid eye disease (TED). The filing acceptance was based on results from the two randomized phase 3, SatraGO-1/ NCT0598